I71.0
Conditions
Interventions
Group 1: Patients who were in the observation phase of drug therapy were monitored by computed tomography for signs of morphological or functional deterioration. The progression of the underlying aort
Sponsors
Universitätsklinik für Allgemein-, Viszeral-, Gefäß- und Transplantationschirurgie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Patients with thoracic aortic aneurysm (TAA) and thoracic type B dissection
Exclusion criteria
Exclusion criteria: - Patients with type A aortic dissection - Patients with non-A-non-B dissection - Patients with thoracoabdominal aortic aneurysm (TAAA)/abdominal aortic aneurysm (AAA)/pelvic artery aneurysm (BAA)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - 30-day or hospital morbidity/mortality - Complication rate and spectrum (especially endoleak rate and spectrum; others, e.g. infection, spinal ischaemia, haemorrhage, malperfusion) | — |
Secondary
| Measure | Time frame |
|---|---|
| - Reintervention characteristics (rate, spectrum, endovascular feasibility) - Other: selected laboratory values (CRP, leukocytes, haemoglobin, thrombocytes, INR, creatinine, protein, potassium, sodium, HTK, albumin, neutrophil granulocytes, length of stay/hospitalisation pre-/post-intervention (normal ward, intensive care unit, IMC) | — |
Countries
Germany
Contacts
Public ContactUdo Barth
Universitätsklinik für Allgemein-, Viszeral-, Gefäß- und Transplantationschirurgie
Outcome results
None listed